MX2018004797A - Formulacion de liberacion prolongada a base de un compuesto de hidrogel. - Google Patents
Formulacion de liberacion prolongada a base de un compuesto de hidrogel.Info
- Publication number
- MX2018004797A MX2018004797A MX2018004797A MX2018004797A MX2018004797A MX 2018004797 A MX2018004797 A MX 2018004797A MX 2018004797 A MX2018004797 A MX 2018004797A MX 2018004797 A MX2018004797 A MX 2018004797A MX 2018004797 A MX2018004797 A MX 2018004797A
- Authority
- MX
- Mexico
- Prior art keywords
- depot formulation
- hydrogel composite
- relates
- silica
- nucleotide
- Prior art date
Links
- 239000002131 composite material Substances 0.000 title abstract 4
- 238000009472 formulation Methods 0.000 title abstract 4
- 239000000017 hydrogel Substances 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 abstract 5
- 230000001684 chronic effect Effects 0.000 abstract 2
- 229940127073 nucleoside analogue Drugs 0.000 abstract 2
- 239000002773 nucleotide Substances 0.000 abstract 2
- 125000003729 nucleotide group Chemical group 0.000 abstract 2
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 abstract 2
- 239000000377 silicon dioxide Substances 0.000 abstract 2
- 208000035415 Reinfection Diseases 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 238000002347 injection Methods 0.000 abstract 1
- 239000007924 injection Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 abstract 1
- 239000000725 suspension Substances 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/32—Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
- A61M5/329—Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles characterised by features of the needle shaft
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Dispersion Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Biotechnology (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Materials For Medical Uses (AREA)
Abstract
Esta invención se refiere a una formulación de liberación prolongada que comprende un compuesto de hidrogel de sílice biodegradable que incorpora un inhibidor de transcriptasa inversa análogo de nucleótido o nucleósido, donde el compuesto de hidrogel de sílice se puede obtener mezclando partículas de sílice que comprenden dicho inhibidor de transcriptasa inversa análogo de nucleótido o nucleósido y que tienen un diámetro máximo de = 1,000 µm, como tal o como una suspensión, con sol de sílice en donde el compuesto de hidrogel no fluye y es estructuralmente estable cuando se almacena en reposo y es pseudoplástico cuando se aplica un esfuerzo de cizalladura por inyección. La presente invención también se refiere al uso de la formulación de liberación prolongada para el tratamiento de infecciones virales crónicas y la prevención de la reinfección viral crónica. La presente invención se refiere además a jeringas precargadas que comprenden dicha formulación de liberación prolongada.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FI20155750 | 2015-10-22 | ||
| PCT/FI2016/050745 WO2017068245A1 (en) | 2015-10-22 | 2016-10-21 | Hydrogel composite depot formulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018004797A true MX2018004797A (es) | 2018-09-06 |
Family
ID=57286528
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018004797A MX2018004797A (es) | 2015-10-22 | 2016-10-21 | Formulacion de liberacion prolongada a base de un compuesto de hidrogel. |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US10172792B2 (es) |
| EP (1) | EP3365020B1 (es) |
| JP (1) | JP6905520B2 (es) |
| KR (1) | KR102228986B1 (es) |
| CN (1) | CN108367076B (es) |
| AU (1) | AU2016342470B2 (es) |
| BR (1) | BR112018006784B1 (es) |
| CA (1) | CA3001752C (es) |
| DK (1) | DK3365020T3 (es) |
| ES (1) | ES2748032T3 (es) |
| HR (1) | HRP20191707T1 (es) |
| HU (1) | HUE046419T2 (es) |
| LT (1) | LT3365020T (es) |
| MX (1) | MX2018004797A (es) |
| PL (1) | PL3365020T3 (es) |
| PT (1) | PT3365020T (es) |
| WO (1) | WO2017068245A1 (es) |
| ZA (1) | ZA201802040B (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019144180A1 (en) * | 2018-01-23 | 2019-08-01 | Ascend Biopharmaceuticals Ltd | Enhanced viral delivery formulation |
| WO2021053167A1 (de) * | 2019-09-19 | 2021-03-25 | Amw Gmbh | Extrudierte depotform mit kontrollierter wirkstofffreisetzung |
| EP4178542B1 (en) * | 2020-07-07 | 2024-12-04 | DelSiTech Oy | Silica hydrogel composite and its use |
| WO2022216928A1 (en) * | 2021-04-07 | 2022-10-13 | Stealth Biotherapeutics Inc. | Silica-based formulations of therapeutic oliogpeptides and peptidomimetics |
| WO2024047230A1 (en) | 2022-09-01 | 2024-03-07 | Optifye Therapeutics Ag | Ophthalmic compositions |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ297042B6 (cs) | 1996-05-29 | 2006-08-16 | Delsitechoy | Dodávkové zarízení pro pomalé uvolnování biologicky úcinného cinidla, jeho pouzití a farmaceutický prostredek s jeho obsahem |
| CN101541939A (zh) * | 2006-11-22 | 2009-09-23 | 阿普尔顿纸张公司 | 含有益剂的递送颗粒 |
| CN101444503B (zh) * | 2008-12-31 | 2011-02-02 | 江苏大学 | 一种水飞蓟宾高效长效制剂及其制法 |
| US8974709B2 (en) * | 2010-06-25 | 2015-03-10 | Colabs Intl Corp | Ceramic encapsulation with controlled layering by use of prehydrolyzed functionalized silanes |
| CA2834365A1 (en) * | 2011-04-28 | 2012-11-01 | Sandia Corporation | Porous nanoparticle-supported lipid bilayers (protocells) for targeted delivery and methods of using same |
| KR101594820B1 (ko) | 2011-06-16 | 2016-02-17 | 건일제약 주식회사 | 엔테카비르를 함유하는 미립구 및 이의 제조방법 |
| ITTO20111242A1 (it) * | 2011-12-30 | 2013-07-01 | Miso S R L | Composizioni per il trattamento di patologie delle mucose |
| HUE047897T2 (hu) * | 2013-06-24 | 2020-05-28 | Delsitech Oy | Szilika tartalmú hidrogél kompozit |
| EP3031449A4 (en) * | 2013-08-06 | 2017-05-10 | Dong Kook Pharm. Co., Ltd | Entecavir microspheres and pharmaceutical composition for parenteral administration containing same |
-
2016
- 2016-10-21 PL PL16794670T patent/PL3365020T3/pl unknown
- 2016-10-21 BR BR112018006784-9A patent/BR112018006784B1/pt active IP Right Grant
- 2016-10-21 KR KR1020187008781A patent/KR102228986B1/ko active Active
- 2016-10-21 AU AU2016342470A patent/AU2016342470B2/en active Active
- 2016-10-21 HR HRP20191707 patent/HRP20191707T1/hr unknown
- 2016-10-21 EP EP16794670.6A patent/EP3365020B1/en active Active
- 2016-10-21 CA CA3001752A patent/CA3001752C/en active Active
- 2016-10-21 LT LT16794670T patent/LT3365020T/lt unknown
- 2016-10-21 ES ES16794670T patent/ES2748032T3/es active Active
- 2016-10-21 HU HUE16794670A patent/HUE046419T2/hu unknown
- 2016-10-21 PT PT167946706T patent/PT3365020T/pt unknown
- 2016-10-21 CN CN201680061622.2A patent/CN108367076B/zh active Active
- 2016-10-21 WO PCT/FI2016/050745 patent/WO2017068245A1/en not_active Ceased
- 2016-10-21 DK DK16794670.6T patent/DK3365020T3/da active
- 2016-10-21 JP JP2018520484A patent/JP6905520B2/ja active Active
- 2016-10-21 US US15/770,034 patent/US10172792B2/en active Active
- 2016-10-21 MX MX2018004797A patent/MX2018004797A/es active IP Right Grant
-
2018
- 2018-03-27 ZA ZA2018/02040A patent/ZA201802040B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US10172792B2 (en) | 2019-01-08 |
| CN108367076A (zh) | 2018-08-03 |
| HUE046419T2 (hu) | 2020-02-28 |
| CA3001752A1 (en) | 2017-04-27 |
| ES2748032T3 (es) | 2020-03-12 |
| ZA201802040B (en) | 2019-07-31 |
| JP6905520B2 (ja) | 2021-07-21 |
| KR102228986B1 (ko) | 2021-03-18 |
| EP3365020A1 (en) | 2018-08-29 |
| CN108367076B (zh) | 2021-08-31 |
| KR20180071253A (ko) | 2018-06-27 |
| LT3365020T (lt) | 2019-10-25 |
| BR112018006784A2 (pt) | 2018-10-16 |
| JP2018531270A (ja) | 2018-10-25 |
| EP3365020B1 (en) | 2019-07-17 |
| AU2016342470B2 (en) | 2019-03-21 |
| WO2017068245A1 (en) | 2017-04-27 |
| BR112018006784B1 (pt) | 2023-10-03 |
| PL3365020T3 (pl) | 2020-03-31 |
| AU2016342470A1 (en) | 2018-04-12 |
| CA3001752C (en) | 2021-10-05 |
| PT3365020T (pt) | 2019-10-24 |
| US20180311150A1 (en) | 2018-11-01 |
| HRP20191707T1 (hr) | 2019-12-13 |
| DK3365020T3 (da) | 2019-10-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018004797A (es) | Formulacion de liberacion prolongada a base de un compuesto de hidrogel. | |
| WO2021123775A3 (en) | Engineered platelets for targeted delivery of a therapeutic agent | |
| IL279036A (en) | Pharmaceutical combination, the composition and preparation of a combination containing an activator of glucokinase and an inhibitor of SGLT-2, preparation methods and their uses | |
| WO2017191258A8 (en) | INFLUENZA MRNA VACCINES | |
| BR112016029041A8 (pt) | uso de um inibidor de glutaminase, composição farmacêutica e kit farmacêutico | |
| WO2018115527A3 (en) | Mers coronavirus vaccine | |
| CA2946953C (en) | An aqueous pharmaceutical composition of adalimumab | |
| CU20170001A7 (es) | Composiciones farmacéuticas de polímero de ácido nucleico fosforotioato y de nucleósido/nucleótido análogo, útiles para el tratamiento de hepatitis b y hepatitis d | |
| MY208610A (en) | Crystalline forms of the 4-pyrimidinesulfamide derivative aprocitentan | |
| MX2016010105A (es) | Derivados de nucleosido sustituidos con 4´ -difluorometilo como inhibidores de la replicacion de arn de la infuenza. | |
| EP4585614A3 (en) | Liquid pharmaceutical composition of adalimumab | |
| MX384890B (es) | Aplicador antiséptico. | |
| TW201613630A (en) | Pharmaceutical compositions | |
| PH12021550705A1 (en) | Stable semaglutide compositions and uses thereof | |
| CR20210126A (es) | Administración prolongada de lasmiditan por la noche para la prevención de la migraña | |
| MX389026B (es) | Una composicion farmaceutica y el uso de la misma. | |
| EP4512407A3 (en) | Oligonucleotides for modulating rtel1 expression | |
| WO2013016278A3 (en) | Modulators of antiviral signaling pathways and therapeutic uses thereof | |
| PT3773682T (pt) | Apresentações injetáveis, seringas e composições de libertação prolongada e/ou controlada de lanreotida | |
| PH12017500817A1 (en) | Long acting pharmaceutical compositions for hepatitis c | |
| PH12017500820A1 (en) | Combination long acting compositions and methods for hepatitis c | |
| MX2016009387A (es) | Una composicion que puede rociarse que contiene oxido de zinc y un propelente de fluoro olefina. | |
| CO2018004240A2 (es) | Copolímeros en bloque como dispersantes para aglutinantes activados con álcalis | |
| WO2014125369A3 (en) | Stable compositions comprising 60bp repeat-deleted gallid herpesvirus-2 (gahv-2) | |
| AR101126A1 (es) | Composiciones para el tratamiento de infecciones por virus de hepatitis b y hepatitis d |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |